Aurinia Pharmaceuticals Inc (AUPH) Stock Price

AUPHStock
$16.75+35.04%52W
Market Cap$2.23B
P/E6.99x
PEG Ratio
Div yield
Beta1.62

AUPH Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)4.55%
Price vs S&P 500 (4W)7.71%
VGM Score68.45
P/E Ratio (Annual)6.99x

AUPH Earnings Surprise History

Q2 250.16est. 0.15
Q3 250.23est. 0.16
Q4 251.53est. 0.22
Q1 260.25est. 0.20
Q2 260.28est. 0.24

AUPH Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
3.92
3.92
3.92
3.92

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
AUPHAurinia Pharmaceuticals Inc
BBB$16.75
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is a biopharmaceutical company specializing in autoimmune diseases with significant unmet medical needs. The company commercializes LUPKYNIS (voclosporin), the first and only FDA-approved oral therapy for active lupus nephritis in adult patients, and is developing aritinercept, a dual BAFF/APRIL inhibitor for additional autoimmune indications.